Inherited and acquired syndromes of hyperammonemia and encephalopathy in children

Seminars in Liver Disease

Volumn 14, Issue 3, 1994, Pages 236-258

  Treem, William R ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; N ACETYLGLUTAMIC ACID;

ACIDEMIA; AMMONIA FORMATION; CLINICAL FEATURE; DISORDERS OF CARBOXYLIC ACID METABOLISM; FATTY ACID OXIDATION; GENE THERAPY; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HYPERAMMONEMIA; HYPERORNITHINEMIA; INBORN ERROR OF METABOLISM; LIVER CYTOSOL; LIVER TRANSPLANTATION; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROTEIN INTOLERANCE; REVIEW; REYE SYNDROME; UREA CYCLE;

EID: 0028068808     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007315     Document Type: Review

References (219)

1. Batshaw ML: Hyperammonemia. Curr Prob Pediatr 14:3-67, 1984.
2. Brusilow SW: Disorders of the urea cycle. Hosp Prac 20:65-72, 1985.
3. Treem WR: Inborn defects in mitochondrial fatty acid oxidation. In: Suchy F, ed: Liver disease in children. St. Louis: Mosby, 1994.
4. Treem WR: Hepatic failure. In; Walker WA, Durie PR, Hamilton JR, et al, eds: Pediatric gastrointestinal disease: pathophysiology, diagnosis, management. Philadelphia: B.C. Decker, 1991.
5. Whittington P: Hepatic failure. In: Suchy F, ed: Liver disease in children. St. Louis: CV Mosby, 1994.
6. Mori M, Morita T, Ikeda F, et al: Synthesis, intracellular transport and processing of the precursors for mitochondrial ornithine transcarbamylase and carbamylphosphate synthetase I in isolated hepatocytes. Proc Natl Acad Sci USA 78:6056-60, 1981.
7. Boehm G, Teichmann B, Jung K: Development of urea-synthesizing capacity in preterm infants during the first weeks of life. Biol Neonate 59:1-4, 1991.
8. Snodgrass PJ: Biochemical aspects of urea cycle disorders. Pediatrics 68:273-83, 1981.
9. Batshaw ML, Walser M, Brusilow SW: Plasma α-ketoglutarate in urea cycle enzymopathies and its role as a harbinger of hyperammonemic coma. Pediatr Res 14:1316-19, 1980.
10. Maestri NE, McGowan DK, Brusilow SW: Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 121:259-61, 1992.
11. Takahashi H, Koehler RC, Brusilow SW, Traystman RJ: Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats. Am J Physiol 261:H825-9, 1991.
12. Eriksson LS, Broberg S, Bjorkman O, Wahren J: Ammonia metabolism during exercise in man. Clin Physiol 5:326-36, 1985.
13. Coakley JH, Wagenmakers AJM, Edwards RHT: Relationship between ammonia, heart rate and exertion in McArdle's disease. Am J Physiol 262:E167-72, 1992.
14. Coude FX, Sweetman L, Nyhan WL: Inhibition by propionylcoenzyme A of N-acetylglutamate synthetase in rat liver mitochondria. J Clin Invest 64:1544-51, 1979.
15. Martin-Requero A, Corkey BE, Cerdan S, et al: Interactions between α-ketoisovalerate metabolism and the pathways of gluconeogenesis and urea synthesis in isolated hepatocytes. J Biol Chem 258:3673-81, 1983.
16. Roe CR, Coates PM: Acyl-CoA dehydrogenase deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1989.
17. Denton EM, McCormack JG, Oviasu OA: Short-term regulation of pyruvate carboxylase activity in the liver. In: Huc L, Van de Werve G, eds. Short-term regulation of liver metabolism, Amsterdam, Elsevier, 1981.
18. Robishaw JD, Neely JR: Coenzyme A metabolism. Am J Physiol 248:E1-9, 1985.
19. Hoppel Cl. Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis. Fed Proc 14:2853-7, 1987.
20. Scholte HR, Rodrigues Pereira R, de Jonge PC, et al: Primary carnitine deficiency. J Clin Chem Clin Biochem 28:351-7, 1990.
21. Vignais PV: Molecular and physiological aspects of adenine nucleotide transport in mitochondria. Biochem Biophys Acta 456:1-38, 1976.
22. Fahien LA, Kmiotek E: Regulation of glutamate dehydrogenase by palmitoyl-coenzyme A. Arch Biochem Biophys 212:247-253, 1981.
23. Fisher MN, Robishaw JD, Neely JR: The properties and regulation of pantothenate kinase from rat heart. J Biol Chem 260:15745-51, 1985.
24. Michalak A, Qureshi IA: Plasma and urinary levels of carnitine in different experimental models of hyperammonemia and the effect of sodium benzoate treatment. Biochem Med Metab Biol 43:163-74, 1990.
25. O'Connor JE, Costell M, Grisolia S: Protective effect of L-carnitine on hyperammonemia. FEBS Lett 166:331-4, 1984.
26. Ohtsuka Y, Griffith OW: L-carnitine protection in ammonia intoxication. Biochem Pharmacol 41:1957-61, 1991.
27. Hearn TJ, Coleman AE, Lai JCK, et al: Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval shunted rats. Hepatology 10:822-9, 1989.
28. Costell M, O'Connor JE, Miguez MP, Grisolia S: Effects of L-carnitine on urea synthesis following acute ammonia intoxication in mice. Biochem Biophys Res Commun 120:726-33, 1984.
29. O'Connor JE, Costell M, Miguez MP, et al: Effect of L-carnitine on ketone bodies, redox state, and free amino acids in the liver of hyperammonemic mice. Biochem Pharmacol 36:3169-73, 1987.
30. Ratnakumari L, Qureshi IA, Butterworth RF: Effects of congenital hyperammonemia on the cerebral and hepatic levels of the intermediates of energy metabolism in spf mice. Biochem Biophys Res Commun 184:746-51, 1992.
31. Ratnakumari L, Qureshi AI, Butterworth RF: Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy. Metabolism 42:1039-46, 1993.
32. Batshaw WL, Brusilow SW: Treatment of hyperammonemic coma caused by inborn errors of urea synthesis. J Pediatr 97:893-900, 1980.
33. Tokatli A, Coskun E, Ozalp I: Fifteen years' experience with 212 hyperammonaemic cases at a metabolic unit. J Inherit Metab Dis 14:698-706, 1991.
34. Batshaw ML, Brusilow SW, Waber L, et al: Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 306:1387-92, 1982.
35. Finkelstein JE, Hauser ER, Leonard CO, Brusilow SW: Late-onset ornithine transcarbamylase deficiency in male patients. J Pediatr 117:897-902, 1990.
36. Drogari E, Leonard JV: Late onset ornithine carbamoyl transferase deficiency in males. Arch Dis Child 63:1363-7, 1988.
37. Horwich AL, Fenton WA, Williams KR, et al: Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase. Science 224:1068-74, 1989.
38. Tuchman M: Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat 2:174-8, 1993.
39. Glasgow AM, Kraegel JH, Schulman JD: Studies of the cause and treatment of hyperammonemia in females with ornithine transcarbamylase deficiency. Pediatrics 62:30-7, 1978.
40. Rowe PC, Newman SL, Brusilow SW: Natural history of symptomatic partial ornithine transcarbamylase deficiency. N Engl J Med 314:541-7, 1986.
41. Batshaw ML, Msall M, Beaudet AL, Trojak J: Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 108:236-41, 1986.
42. Girgis N, McGravey V, Shah BL, et al: Lethal ornithine transcarbamylase deficiency in a female neonate. J Inherit Metab Dis 10:274-5, 1987.
43. Hamano Y, Kodama H, Fujikawa Y, et al: Use of immunocytochemical analysis of a duodenal biopsy specimen to identify a carrier of ornithine transcarbamylase deficiency. N Engl J Med 318:1521-3, 1988.
44. Bachman C: Urea-cycle disorders. In: Fernandez J, Saudubray JM, Tada K, eds. Inborn metabolic diseases: diagnosis and treatment. New York: Springer-Verlag, 1990.
45. Gilchrist JM. Coleman RA: Ornithine transcarbamylase deficiency: adult onset of severe symptoms. Ann Intern Med 106:556-8, 1987.
46. Rottem MM, Statter M, Amit R, et al: Clinical and laboratory study in 22 patients with inherited hyperammonemic syndromes. Israel J Med Sci 22:833-6, 1986.
47. Breningstall GN: Neurologic syndromes in hyperammonemic disorders. Pediatr Neurol 2:253-62, 1986.
48. Lo WD, Sloan RH, Sotos JF, Klinger RJ: Late clinical presentation of partial carbamyl phosphate synthetase I deficiency. Am J Dis Child 147:267-9, 1993.
49. Msall M, Batshaw ML, Suss R, et al: Neurologic outcome in children with inborn errors of urea synthesis. N Engl J Med 310:1500-5, 1984.
50. Hauser ER, Finkelstein JE, Valle D, Brusilow SW: Allopurinol-induced orotidinuria: a test for mutations at the ornithine transcarbamylase locus. N Engl J Med 322:1641-5, 1990.
51. Batshaw ML, Roan Y, Jung AI, et al: Cerebral dysfunction in asymptomatic carriers of ornithine transcarbamylase deficiency. N Engl J Med 302:482-5, 1980.
52. Bachmann C: Ornithine carbamoyl transferase deficiency: findings, models and problems. J Inherit Metab Dis 15:578-91, 1992.
53. Goldblum OM, Brusilow SW, Maldonado YA, Fanner EI: Neonatal citrullinemia associated with cutaneous manifestations and arginine deficiency. J Am Acad Dermatol 14:321-6, 1986.
54. LaBrecque DR, Latham PS, Riely CA, et al: Heritable urea cycle enzyme deficiency-liver disease in 16 patients. J Pediatr 94:580-7, 1979.
55. Bove KE, McAdams AJ, Partin JC, et al: Hepatic lesion in Reye syndrome. Gastroenterology 69:685-97, 1975.
56. Treem WR, Witzleben CA, Picolli DA, et al: Medium-chain and long-chain acyl CoA dehydrogenase deficiency: clinical, pathologic, and ultrastructural differentiation from Reye's syndrome. Hepatology 6:1270-8, 1986.
57. Zimmerman A, Bachmann C, Baumgartner R: Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med 110:136-40, 1986.
58. Zimmerman A, Bachmann C, Schubiger G: Liver pathology in a new congenital disorder of urea synthesis: N-acetylglutamate synthetase deficiency. Virchows Arch 408:259-68, 1985.
59. Parsons HG, Scott RB, Pinto RJ, Snyder FF: Argininosuccinic aciduria: long-term treatment with arginase. J Inherit Metab Dis 10:152-61, 1987.
60. Zimmerman A, Bachmann C, Colombo JP: Ultrastructural pathology in congenital defects of the urea cycle: ornithine transcarbamylase and carbamylphosphate synthetase deficiency. Virchow Arch (Pathol Anat) 12:212-23, 1981.
61. Tallan HH, Schaffner F, Taffet SL, et al: Ornithine carbamoytransferase deficiency in an adult male patient: significance of hepatic ultrastructure in clinical diagnosis. Pediatrics 71:224-32, 1983.
62. Partin JC, Schubert WK, Partin JS: Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). N Engl J Med 285:1339, 1971.
63. Fox J, Hack AM, Fenton WA, et al: Prenatal diagnosis of ornithine transcarbamylase deficiency with use of DNA polymorphisms. N Engl J Med 315:1205-8, 1986.
64. Shih VE, Mandell R, Herzfeld A: Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria. Clin Chim Acta 118:149-57, 1982.
65. Inoue I, Saheki T, Kayanuma K, et al: Biochemical analysis of decreased ornithine transport activity in the liver mitochondria from patients with hyperornithinemia, hyperammonemia and homocitrullinuria. Biochim Biophys Acta 964:90-5, 1988.
66. Botschner J, Smith DW, Simell O, Scriver CR: Comparison of ornithine metabolism in hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome, lysinuric protein intolerance and gyrate atrophy fibroblasts. J Inherit Metab Dis 12:33-40, 1989.
67. Gjessing LR, Lunde HA, Undrum T, et al: A new patient with hyperornithinaemia, hyperammonaemia and homocitrullinuria treated early with low protein diet. J Inherit Metab Dis 9:186-92, 1986.
68. Nakajima M, Ishii S, Mito T, et al: Clinical, biochemical and ultrastructural study on the pathogenesis of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Brain Dev 10:181-5, 1988.
69. Oyanagi K, Tsuchiyama A, Itakura Y, et al: The mechanism of hyperammonemia and hyperornithinaemia in the syndrome of hyperornithinaemia, hyperammonaemia with homocitrullinuria. J Inherit Metab Dis 6:133-4, 1983.
70. Shih VE, Laframboise R, Mandell R, Pichette J: Neonatal form of the hyperornithinaemia, hyperammonaemia and homocitrullinuria (HHH) syndrome and prenatal diagnosis. Prenatal Diagn 12:717-23, 1992.
71. Dionisi-Vici CD, Bachmann C, Gambarara M, et al: Hyperornithinaemia-hyperammonemia-homocitrullinuria syndrome: low creatinine excretion and effect of citrulline, arginine, or ornithine supplement. Pediatr Res 22:364-7, 1987.
72. Tuchman M, Knopman DS, Shih VE: Episodic hyperammonemia in adult siblings with hyperornithinaemia, hyperammonemia, and homocitrullinuria syndrome. Arch Neurol 47:1134-7, 1990.
73. Lemay JF, Lambert MA, Mitchell GA, et al: Hyperammonemia-hyperornithinaemia-homocitrullinuria syndrome: neurologic ophthalmologic, and neuropsychologic examination of six patients. J Pediatr 121:725-30, 1992.
74. Smith L, Lambert MA, Brochu P, et al: Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome: presentation as acute liver disease with coagulopathy. J Pediatr Gastroenterol Nutr 15:431-6, 1992.
75. Haust MD, Gatfield PD, Gordon BA: Ultrastructure of hepatic mitochondria in a child with hyperornithinemia, hyperammonemia and homocitrullinemia. Hum Pathol 12:212-23, 1987.
76. Fell V, Pollitt RJ, Sampson GA, Wright T: Ornithinimia, hyperammonemia, and homocitrullinemia. A disease associated with mental retardation and possibly caused by defective mitochondrial transport. Am J Dis Child 127:752-6, 1974.
77. Simell O, Mackenzie S, Clow CL, Scriver CR: Ornithine loading did not prevent induced hyperammonemia in a patient with hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Pediatr Res 19:1283-7, 1985.
78. Simell O, Perheentupa J, Rapola J, et al: Lysinuric protein intolerance. Am J Med 59:229-40, 1979.
79. Rajantie J, Simell O, Perheentupa J: Basolateral and mitochondrial membrane transport defect in the hepatocytes in lysinuric protein intolerance. Acta Pediatr Scand 72:65-70, 1983.
80. Kato T, Mizutani N, Ban M: Hyperammonemia in lysinuric protein intolerance. Pediatrics 73:489-92, 1984.
81. Kerem E, Elpelg ON, Shalev RS, et al: Lysinuric protein intolerance with chronic interstitial lung disease and pulmonary cholesterol granulomas at onset. J Pediatr 123:275-8, 1993.
82. Rajantie J, Simell O, Rapola J, et al: Lysinuric protein intolerance: a 2 year trial of dietary supplementation therapy with citrulline and lysine. J Pediatr 97:927-32, 1980.
83. Mizutani K, Kato T, Maehara M, et al: Oral administration of arginine and citrulline in the treatment of lysinuric protein intolerance. Tohoku J Exp Med 142:15-24, 1984.
84. Fuchshuber A, Suormala T, Roth B, et al: Holocarboxylase synthetase deficiency: early diagnosis and management of a new case. Eur J Pediatr 152:446-9, 1993.
85. Michalski AJ, Berry GT, Segal S: Holocarboxylase synthetase deficiency: 9 year follow-up of a patient on chronic biotin therapy and a review of the literature. J Inherit Metab Dis 12:312-6, 1989.
86. Danner DJ, Elias LJ: Disorders of branched chain amino acid and ketoacid metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1989.
87. Roe CR, Millington DS, Maltby DA, et al: L-carnitine enhances excretion of propionyl coenzyme A as propionyl carnitine in propionic acidemia. J Clin Invest 73:1785-8, 1984.
88. Wolf B, Hsia YE, Tanaka K, et al: Correlation between serum propionate and blood ammonia concentrations in propionic acidemia. J Pediatr 93:471-3, 1978.
89. Wolf B, Hsia YE, Sweetman L, et al: Propionic acidemia: a clinical update. J Pediatr 99:835-46, 1981.
90. Roe CR, Millington DS, Maltby DA, et al: L-carnitine in isovaleric acidemia. J Clin Invest 74:2290-5, 1984.
91. Kreiger I, Tanaka K: Therapeutic effects of glycine in isovaleric acidemia. Pediatr Res 10:25-9, 1976.
92. Wolf B: Reassessment of biotin-responsiveness in "unresponsive" propionyl CoA carboxylase deficiency. J Pediatr 97:964-6, 1980.
93. Mahoney MJ, Bick D: Recent advances in the inherited methylmalonic acidemias. Acta Paediatr Scand 76:689-96, 1987.
94. Bain MD, Jones M, Borrielo SP, et al: Contribution of gut bacterial metabolism to human metabolic disease. Lancet 1:1078-9, 1988.
95. 14C-labeled substrates in humans. J Clin Invest 79:359-66, 1987.
96. Felig P, Wahren J: Fuel homeostasis in exercise. N Engl J Med 293:1078-84, 1975.
97. McGarry JD, Foster DW: Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49:395-420, 1980.
98. Marsden D, Sege-Petersen K, Nyhan WL, et al: An unusual presentation of medium-chain acyl Co-enzyme A dehydrogenase deficiency. Am J Dis Child 146:1459-62, 1992.
99. Rowe PC, Valle D, Brusilow SW: Inborn errors of metabolism in children referred with Reye's syndrome. JAMA 260:3167-70, 1988.
100. Matsubara Y, Narisawa K, Tada K, et al: Prevalence of K329E mutation in medium-chain acyl-CoA dehydrogenase gene determined from Guthrie cards. Lancet 338:552-3, 1991.
101. Treem WR, Stanley CA, Hale DE, et al: Hypoglycemia, hypotonia, and cardiomyopathy: the evolving clinical picture of long-chain acyl-CoA dehydrogenase deficiency. Pediatrics 87:328-33, 1991.
102. Cole DEC, Clarke LA, McPhee MD, et al. Hyperuricemia in disorders of fatty acid oxidation. Clin Chem 34:795-6, 1988.
103. Gruskay JA, Rosenberg LE: Inhibition of hepatic mitochondrial carbamyl phosphate synthetase (CPS I) by acyl CoA esters: possible mechanism of hyperammonemia in organic acidurias. (Abstr.) Pediatr Res 13:475, 1979.
104. Derr RF, Zieve L: Effect of fatty acids on the disposition of ammonia. J Pharmacol Exp Ther 197:675-80, 1976.
105. Treem WR, Rinaldo P, Hale DE, et al: Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Hepatology 19:339-345, 1994.
106. Bennett MJ: The laboratory diagnosis of inborn errors of mitochondrial fatty acid oxidation. Ann Clin Biochem 27:519-31, 1990.
107. Gregerson N, Andersen BS, Bross P, et al: Molecular characterization of medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci USA 87:9236-9240, 1990.
108. Stanley CA, Sunaryo F, Hale DE, et al: Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency. J Inherit Metab Dis 15:785-9, 1992.
109. Treem WR, Stanley CA, Finegold DN, et al: Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 319:1331-6, 1988.
110. Robinson BH, Sherwood WG: Lactic acidaemia. J Inherit Metab Dis 7:69-73, 1984.
111. Robinson BH, Oei J, Sherwood WG, et al. The molecular basis for the two different clinical presentations of classical pyruvate carboxylase deficiency. Am J Hum Genet 36:283-94, 1984.
112. Greter J, Gustafsson J, Holme E: Pyruvate-carboxylase deficiency with urea cycle impairment. Acta Paediatr Scand 74:982-6, 1985.
113. Matsuo M, Ookita K, Takemine H, et al: Fatal case of pyruvate carboxylase deficiency. Acta Paediatr Scand 74:140-2, 1985.
114. Brown GK, Scholem RD, Hunt SM, et al: Hyperammonaemia and lactic acidosis in a patient with pyruvate carboxylase deficiency. J Inherit Metab Dis 10:359-66, 1987.
115. Byrd DJ, Krohn HP, Winkler L: Neonatal pyruvate carboxylase deficiency with lipoate responsive lactic acidaemia and hyperammonaemia. Eur J Pediatr 148:543-7, 1989.
116. Wexler ID, Kerr DS, Ho L, et al: Heterogenous expression of protein and mRNA in pyruvate carboxylase deficiency. Proc Natl Acad Sci USA 85:7336-40, 1988.
117. McCormick K, Viscardi RM, Robinson B, Heininger J: Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate. Am J Med Genet 22:291-9, 1985.
118. Toth P, El-Shanti H, Elvins S, et al: Transient improvement of congenital lactic acidosis in a male infant with pyruvate decarboxylase deficiency treated with dichloroacetate. J Pediatr 123:427-40, 1993.
119. Batshaw ML, Brusilow SW: Asymptomatic hyperammonemia in low birthweight infants. Pediatr Res 12:221-4, 1978.
120. Batshaw ML, Wachtel RC, Thomas GH, et al: Arginine-responsive asymptomatic hyperammonemia in the premature infant. J Pediatr 105:86, 1984.
121. Nakamura T, Nakamura S, Kondo Y, et al: Carnitine status and blood ammonium levels in low birth weight infants. J Pediatr Gastroenterol Nutr 10:66-70, 1990.
122. Hudak ML, Jones MD, Brusilow SW: Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 107:712-9, 1985.
123. Ballard RA, Vinocur B, Reynolds JW, et al: Transient hyperammonemia of the preterm infant. N Engl J Med 299:920, 1978.
124. Tuchman M, Georgieff MK: Transient hyperammonemia of the newborn: a vascular complication of prematurity? J Perinatol 12:234-6, 1992.
125. Eggermont E, Devilieger H, Marchai G, et al: Angiographic evidence of low portal liver perfusion in transient neonatal hyperammonaemia. Acta Paediatr Belg 33:163-4, 1980.
126. van Geet C, Vandenbossche L, Eggermont E, et al: Possible platelet contribution to the pathogenesis of transient neonatal hyperammonaemia syndrome. Lancet 337:73-5, 1991.
127. Goldberg RN, Cabal LA, Sinatra FR, et al: Hyperammonemia associated with perinatal asphyxia. Pediatrics 64:336-41, 1979.
128. DeVivo D: Reye syndrome. Neurol Clin North Am 3:95-115, 1985.
129. Lovejoy FH, Smith AI, Bresnan MJ, et al: Clinical staging in Reye syndrome. Am J Dis Child 128:36-41, 1974.
130. Brown T, Hug G, Lansky L, et al: Transiently reduced activity of carbamyl phosphate synthetase and ornithine transcarbamylase in liver of children with Reye's syndrome. N Engl J Med 294:861-7, 1976.
131. Mitchell RA, Ram ML. Arcinue EL, Chang CH: Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye syndrome. Pediatr Res 14:1216-21, 1980.
132. Woodfin BM. Davis LE: Displacement of hepatic carbamoyl-transferase from mitochondria to cytosol in Reye's syndrome. Biochem Med Metab Biol 46:255-62, 1991.
133. Snodgrass PJ, Delong GR: Urea-cycle enzyme deficiencies and an increased nitrogen load producing hyperammonemia in Reye's syndrome. N Engl J Med 294:855-60, 1976.
134. Faraj BA, Caplan DB, Newman SL, et al: Hypercatecholaminemia in Reye's syndrome. Pediatrics 73:481-8, 1984.
135. Ogburn PL, Sharp H, Lloyd-Still JD, et al: Abnormal polyunsaturated fatty acid patterns of serum lipids in Reye's syndrome. Proc Natl Acad Sci USA 79:908-11, 1982.
136. Larrick JW, Kunkel SL: Is Reye's syndrome caused by augmented release of tumor necrosis factor? Lancet 2:32-3, 1986.
137. Yoder MC, Egler JM, Yudkoff J, et al: Metabolic and mitochondrial morphological changes that mimic Reye syndrome after endotoxin administration to rats. Infect Immun 47:329-31, 1985.
138. Heubi JE, Partin JC, Partin JS, Schubert WK: Reye's syndrome: current concepts. Hepatology 7:155-64, 1987.
139. Tonsgard JH: Serum dicarboxylic acids in patients with Reye syndrome. J Pediatr 109:440-445, 1986.
140. Corkey BE, Hale DE, Glennon MC, et al: Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest 82:782-8, 1988.
141. Yoshida Y, Fujii M, Brown R, Singh I: Effect of salicylic acid on mitochondrial-peroxisomal fatty acid catabolism. Pediatr Res 23:338-41, 1988.
142. Trauner DA, Horvath E, David LE: Inhibition of fatty acid β-oxidation by influenza B virus and salicylic acid in mice. Implications for Reye's syndrome. Neurology 38:239-41, 1988.
143. Maddiah VT, Miller PS: Effects of ammonium chloride, salicylate, and carnitine on palmitic acid oxidation in rat liver slices. Pediatr Res 25:119-23, 1989.
144. Deschamps D, Fisch C, Fromenty B, et al: Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye syndrome. J Pharmacol Exp Ther 259:894-904, 1991.
145. Kilpatrick-Smith L, Douglas D, Corkey BE: Effects of sublethal doses of endotoxin and aspirin on rat hepatic energy metabolism: an animal model of Reye syndrome. (Abstr.) Pediatr Res 21:343, 1987.
146. Schwarz KB, Arey BJ, Tolman K, Mohanty S: Iron chelation as a possible mechanism for aspirin-induced malondialedehyde production by mouse liver microsomes and mitochondria. J Clin Invest 81:165-80, 1988.
147. Schwarz KB, Moore TJ, Clemens MG, Seligman P: Influenza B-virus promotes lipid peroxidation (LP) in HEP G2 cells via effects on iron metabolism. (Abstr.) Hepatology 14:131A, 1992.
148. Yoshida Y, Singh I, Singh AK, et al: Reye syndrome: rate of oxidation of fatty acids in leukocytes and serum levels of lipid peroxides. J Exp Pathol 4:133-9, 1989.
149. Zimmerman HJ, Ishak KG: Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2:591-7, 1982.
150. Suchy FJ, Balistreri WF, Buchino JJ, et al: Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 300:962-6, 1979.
151. Dreifuss FE, Santilli N, Langer DH, et al: Valproic acid and hepatic fatalities: a retrospective review. Neurology 37:379-85, 1987.
152. Coulter DL, Allen RJ: Hyperammonemia with valproic acid therapy. J Pediatr 317-9, 1981.
153. Batshaw ML, Brusilow SW: Valproate-induced hyperammonemia. Ann Neurol 2:319-21, 1981.
154. Iinuma K, Hayasaka K, Narisawa K, et al: Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid. Eur J Pediatr 148:267-9, 1988.
155. Haidukewych D, John G, Zielinski JJ, Rodin EA: Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit 7:290-4, 1985.
156. Ratnaike RN, Schapel GJ, Purdie G, et al: Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 22:100-3, 1986.
157. Hjelm M, DeSilva LV, Seakins JWT, Oberholzer VG: Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 292:23-4, 1986.
158. Morgan HB, Swaiman KF, Johnson BD: Diagnosis of argininosuccinic aciduria after valproic acid-induced hyperammonemia. Neurology 37:886-7, 1987.
159. Tokatli A, Coskum T, Cataltepe, Ozalp I: Valproate-induced lethal hyperammonaemic coma in a carrier of ornithine carbamoyltransferase deficiency. J Inherit Metab Dis 14:836-7, 1991.
160. Hjelm M, Oberholzer V, Seakins J, et al: Valproate-induced inhibition of urea synthesis and hyperammonaemia in healthy subjects. Lancet 2:859-62, 1986.
161. Coude FX, Rabier D, Cathelineau L, et al: A mechanism for valproate-induced hyperammonemia. Pediatr Res 15:975-8, 1986.
162. Kesterson JW, Granneman GR, Machinist JM: The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4:1143-52, 1984.
163. Granneman GR, Wang SI, Kesterson JW, Machinist JW: The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 4:1153-8, 1984.
164. Thurston JH, Hauhart RE: Reversal of the adverse chronic effects of the unsaturated derivative of valproic acid-2-n-propyl-4-pentenoic acid-on ketogenesis and liver coenzyme-A metabolism by a single injection of pantothenate carnitine, and acetylcystine in developing mice. Pediatr Res 33:72-6, 1993.
165. Holland PC, Senior AE, Sherratt HSA: Biochemical effects of the hypoglycaemic compound pent-4-enoic acid and related non-hypoglycaemic fatty acids. Effects of their co-enzyme A esters on enzymes of fatty acid oxidation. Biochem J 136:173-84, 1973.
166. Kondo T, Ishida M, Kanedo S, et al: Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia? Epilepsia 33:550-4, 1992.
167. Turnbull DM, Dick DJ, Wilson L, et al: Valproate causes metabolic disturbance in normal man. J Neurol Neurosurg Psychiatry 49:405-10, 1986.
168. Hayasaka K, Takahashi I, Kobayshi Y, et al: Effects of valproate on biogenesis and function of live mitochondria. Neurology 36:351-6, 1982.
169. Ohtani Y, Endo F, Matsuda I: Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782-5, 1982.
170. Thom H, Carter PE, Cole GF, Stevenson KL: Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsants drugs. Dev Med Child Neurol 33:795-802, 1991.
171. Matsuda I, Ohtani Y, Ninomiya N: Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 109:131-4, 1986.
172. Coulter DL: Carnitine, valproate, and toxicity. J Child Neurol 6:7-14, 1991.
173. Vance CK, Vance WH, Winter SC, et al: Control of valproate induced hepatotoxicity with carnitine. (Abstr.) Ann Neurol 26:456, 1989.
174. Murphy JV, Groover RV, Hodge C: Hepatotoxic effects in a child receiving valproate and carnitine. J Pediatr 318-20, 1993.
175. Kitagawa S, Gleason WA, Northrup H, et al: Symptomatic hyperammonemia caused by a congenital porosystemic shunt. J Pediatr 121:917-9, 1992.
176. Maisawa S, Takasago Y, Oyake Y, et al: Patent ductus venosus with hypoplastic right hepatoportal system in a young child born with asymmetric intra-uterine growth retardation. Eur J Pediatr 151:569-72, 1992.
177. Voorhees AB, Chaitman E, Schneider S, et al: Portal-systemic encephalopathy in the non-cirrhotic patient. Arch Surg 107:659-63, 1973.
178. Hassall E, Benson L, Hart M, et al: Hepatic encephalopathy after portocaval shunt in a non-cirrhotic child. J Pediatr 105:439-41, 1984.
179. Gonzales ER, Hastings JC, Morton D, Walker LG: Hepatic encephalopathy induced by small bowel obstruction in a noncirrhotic child with portal vein thrombosis. J Pediatr Surg 25:1276-7, 1990.
180. Leonard JV, Kay JDS: Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 287:162-3, 1986.
181. Mitchell RB, Wagner JE, Karp JE: Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 85:662-7, 1988.
182. Samtoy B, DeBeukelaer MM: Ammonia encephalopathy secondary to urinary tract infection with Proteus mirabilis. Pediatrics 65:294-6, 1980.
183. Goldstein B, Brown M, Hulburt WC, Rabinowitz R: Hyperammonemic encephalopathy secondary to diphtheroid urinary tract infection in a patient with prune belly syndrome. Crit Care Med 19:578-80, 1991.
184. Diamond DA, Blight A, Ransley PG: Hyperammonemiac encephalopathy: a complication associated with the prune belly syndrome. J Urol 142:361-2, 1989.
185. Kuntze JR, Weinberg AC. Ahlering TE: Hyperammonemiac coma due to proteus infection. J Urol 134:972-3, 1985.
186. Drayna CJ, Titcomb CP, Varma RR, et al: Hyperammonemic encephalopathy caused by infection in a neurogenic bladder. N Engl J Med 304:766, 1981.
187. Sinha B, Gonzalez R: Hyperammonemia in a boy with obstructive ureterocele and proteus infection. J Urol 131:330-1, 1984.
188. Rutledge SL, Havens PL, Haymond MW, et al: Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism. J Pediatr 116:125-8, 1990.
189. Gortner L, Deupold D, Pohlandt, Bartmann P: Peritoneal dialysis in the treatment of metabolic crises caused by inherited disorders of organic and amino acid metabolism. Acta Paediatr Scand 78:706-11, 1989.
190. Sperl W, Geiger H, Maurer C, et al: Continuous arteriovenous haemofiltration in a neonate with hyperammonaemic coma due to citrullinaemia. J Inherit Metab Dis 15:158-9, 1992.
191. Brusilow SW, Danney M, Waber LJ: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310:1630-4, 1984.
192. Batshaw ML, Monahan PS: Treatment of urea cycle disorders. Enzyme 38:242-50, 1987.
193. van de Bor M, Mooy P, van Zoeren D, et al: Successful treatment of severe carbamyl phosphate synthetase I deficiency. Arch Dis Child 59:1183-5, 1984.
194. Melnyk AR, Matalon R, Henry BW: Prospective management of a child with neonatal citrullinemia. J Pediatr 122:96-8, 1993.
195. Tuchman M, Mauer SM, Holzknecht RA, et al: Prospective versus clinical diagnosis and therapy of acute neonatal hyperammonaemia in two sisters with carbamyl phosphate synthetase deficiency. J Inherit Metab Dis 15:269-77, 1992.
196. Donn SM, Thoene JG: Prospective prevention of neonatal hyperammonaemia in argininosuccinic aciduria by arginine therapy. J Inherit Metab Dis 8:18-20, 1985.
197. Maestri NE, Hauser EF, Bartholomew D, Brusilow SW: Prospective treatment of urea cycle disorders. J Pediatr 119:923-8, 1991.
198. Sushma S, Dasarathy S, Tandon RK: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16:138-44, 1992.
199. Mendenhall CL, Rooser S, Marshall L, et al: A new therapy for portal systemic encephalopathy. Am J Gastroenterol 81:540-3, 1986.
200. Barshop BA, Breuer J, Holm J, et al: Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia. J Inherit Metab Dis 12:72-9, 1989.
201. Shinka T, Inoue Y, Kuhara T, et al: Benzoylalanine: detection and identification of an alanine conjugate with benzoic acid in hyperammonemic patients treated with sodium benzoate. Clin Chim Acta 151:293-300, 1985.
202. O'Connor JE, Ribelles M, Grisolia S: Potentiation of hyperammonemia by sodium benzoate in animals. A note of caution. Eur J Pediatr 138:186-7, 1982.
203. Palekar AG, Canas JA, Kalbag SS, et al: Failure of sodium benzoate to alleviate plasma and liver ammonia in rats. Biochem Med Metab Biol 40:133-45, 1988.
204. Oyanagi K, Kuniya Y, Tsuchiyama A, et al: Nonlinear elimination of benzoate in patients with congenital hyperammonemia. J Pediatr 110:634-6, 1987.
205. Cyr DM, Maswoswe SM, Tremblay GC: Inhibition of the urea cycle and de novo pyrimidine biosynthesis by sodium benzoate. J Inherit Metab Dis 10(suppl 2):308-90, 1987.
206. Sakuma T: Alteration of urinary carnitine profile induced by benzoate
207. Gregus Z, Fekete T, Varga F: Availability of glycine and coenzyme A limits glycine conjugation in vivo. Drug Metab Dispos 20:234-40, 1992.
208. Matsuda I, Ohtani Y, Ohyanagi K, et al: Hyperammonemia related to carnitine metabolism with particular emphasis on ornithine transcarbamylase deficiency. Enzyme 38:251-5, 1987.
209. Ohtani Y, Kazuhiko O, Yamamoto S, Ichiro M: Secondary carnitine deficiency in hyperammonemic attacks of orithine transcarbamylase deficiency. J Pediatr 112:409-14, 1988.
210. Mori T, Tsuchiyama, Nagai K, et al: A case of carbamylphosphate synthetase-I deficiency associated with secondary carnitine deficiency-L-carnitine treatment of CPS-I deficiency. Eur J Pediatr 149:272-4, 1990.
211. Mayatepek E, Kurczynski TW, Hoppel CL, Gunning WT: Carnitine deficiency associated with ornithine transcarbamylase deficiency. Pediatr Neurol 7:196-9, 1991.
212. Brusilow SW: Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis. J Clin Invest 74:2144-8, 1984.
213. Wendel U, Wieland J, Bremer HJ, Bachmann C: Ornithine transcarbamylase deficiency in a male: strict correlation between metabolic control and plasma arginine concentration. Eur J Pediatr 148:349-52, 1989.
214. Bachman C: Treatment of congenital hyperammonemias. Enzyme 32:56-64, 1984.
215. Iafolla AK, Gale DS, Roe CR: Citrate therapy in argininosuccinate lyase deficiency. J Pediatr 117:102-5, 1990.
216. Bachman C, Colombo JP: Acid-base status and plasma glutamine in patients with hereditary urea cycle disorders. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E, eds. Advances in ammonia metabolism and hepatic encephalopathy. Amsterdam: Elsevier Science, 1988.
217. Todo S, Starzl TE, Tzakis A: Orthotopic liver transplantation for urea cycle enzyme deficiency. Hepatology 15:419-22, 1992.
218. Wood PA, Herman GE, Chao CYJ, et al: Retrovirus-mediated gene transfer of argininosuccinate synthetase into cultured rodent cells and human citrullinemic fibroblasts. Cold Spring Harb Symp Quart Biol 51:1027-34, 1986.
219. Morsy MA, Alford EL, Bett A, et al: Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest 92:1580-6, 1993.